Xenon halts phase 3 depression trials after psychosis reports
The voluntary pause raises safety questions about azetukalner just as the FDA reviews the same drug for epilepsy.
Xenon Pharmaceuticals has voluntarily paused enrollment in its phase 3 depression trials after patients experienced psychosis-related adverse events. The company said the events were mostly mild or moderate in severity, but the decision to halt new enrollment signals a notable safety concern.
The news rattled investors, with shares falling as the "neuropsychiatric" events fueled doubts about the drug's prospects. The setback is especially significant because the same therapy, azetukalner, is already under review by the FDA for a form of epilepsy, giving the safety signal broader regulatory implications.
Both sources agree on the core facts: the pause was voluntary and stemmed from adverse events in the depression studies. They differ in emphasis, with one source highlighting the company's characterization of the events as mostly mild or moderate, while the other focuses on the market reaction and the drug's pending epilepsy review.
Sources · 2
More in Medicine & Biotech
Ebola Vaccine Trial Launches in DR Congo Outbreak Zone
Health workers in DR Congo have begun testing whether a vaccine designed for a different Ebola strain can protect against the current outbreak.
Beacon Gene Therapy for Rare Vision Loss Succeeds in Pivotal Trial
A pivotal trial of Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa improved visual acuity, clearing the path toward an FDA submission.
Alkermes orexin agonist shows early promise for ADHD
Early-stage data suggest Alkermes' orexin agonist could expand the drug class beyond sleep disorders into ADHD.
Telix to Buy ITM for $1.65B, Challenging Novartis in Radiopharma
The acquisition gives Telix a late-stage pipeline and supply network that could compete with Novartis' Lutathera.